Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients with FH with hypercholesterolemia. LA reduces LDL-C levels by more than 60% in patients with FH and reduces CVD events. LA also reduces Lp(a) levels and CVD events. LA reduces inflammatory markers and blood viscosity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccl.2015.02.002 | DOI Listing |
Publication Analysis
Top Keywords
cvd events
12
lipoprotein apheresis
8
ldl-c levels
8
events reduces
8
apheresis patients
4
patients familial
4
familial hypercholesterolemia
4
hypercholesterolemia early
4
early development
4
development atherosclerosis
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!